|Price and Volume|
|52 Week High||42.50|
|52 Week Low||20.02|
|Avg. Daily Vol. (Mil)||1.28|
|Beta (3 year)||0.93|
|Share Related Items|
|Mkt Cap (Mil)||2,820.86|
|Shares Out (Mil)||74.82|
|LT Debt/ Equity||0.00|
|Total Debt / Equity||0.00|
|Per Share Data|
|Myriad Genetics Inc is engaged in the discovery and commercialization of transformative tests which assess a persons risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.|
|320 Wakara Way
Salt Lake City, UT 84108
|Industry : Diversified Services|
|CEO: Mr. Peter D. Meldrum|
|Current Month (Mil)||38.04|
|Previous Month (Mil)||37.51|
|Short Interest Ratio (Days)||33.10|
|Return on Equity||25.80|
|Return on Assets||22.90|
|Return on Investments||25.80|
|Rating||Current||1-Mo Ago||2-Mo Ago||3-Mo Ago|
|GET MYGN ANALYST REPORT|
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.